<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epigenetic control of transcription is essential for mammalian development and its deregulation causes human disease </plain></SENT>
<SENT sid="1" pm="."><plain>For example, loss of proper imprinting control at the IGF2-H19 domain is a hallmark of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and <z:e sem="disease" ids="C0004903" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Beckwith-Wiedemann syndrome</z:e>, with no targeted therapeutic approaches available </plain></SENT>
<SENT sid="2" pm="."><plain>To address this deficiency, we engineered zinc-finger transcription proteins (ZFPs) that specifically activate or repress the IGF2 and H19 genes in a domain-dependent manner </plain></SENT>
<SENT sid="3" pm="."><plain>Importantly, we used these ZFPs successfully to reactivate the transcriptionally silent IGF2 and H19 alleles, thus overriding the natural mechanism of imprinting and validating an entirely novel avenue for 'transcription therapy' of human disease </plain></SENT>
</text></document>